Meningococcal vaccine evolution

Area of Science:

• Microbiology
• Immunology
• Vaccinology

Background:

• Neisseria meningitidis is a primary cause of bacterial sepsis and meningitis worldwide, leading to significant mortality and morbidity.
• Invasive meningococcal disease (IMD) incidence varies geographically and by serogroup, with a substantial burden in developing nations.
• Existing polysaccharide vaccines are less effective in infants, a high-risk group.

Purpose of the Study:

• To review the development and effectiveness of vaccines against Neisseria meningitidis.
• To highlight the challenges in preventing meningococcal B disease.
• To discuss the impact of conjugate vaccines on disease incidence.

Main Methods:

• Literature review of Neisseria meningitidis epidemiology and vaccine development.
• Analysis of vaccine efficacy data for polysaccharide and conjugate vaccines.
• Examination of serogroup distribution and disease burden.

Main Results:

• Conjugate vaccines targeting serogroups A, C, W-135, and Y have significantly reduced disease incidence.
• Serogroup C meningococcal conjugate vaccines, introduced in 1999, led to dramatic decreases in disease.
• Despite advances, no broadly effective vaccine is currently available for meningococcal B disease prevention.

Conclusions:

• Vaccine development has made progress in controlling several serogroups of Neisseria meningitidis.
• There is an unmet need for a broadly effective vaccine against serogroup B, which remains a significant public health concern.
• Conjugate vaccine technology has proven successful in inducing T cell-dependent immunity and immunological memory from infancy.